Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy

被引：3
作者：
Hoyle, Christopher [1 ]
Dyer, Matthew [1 ]
机构：
[1] AstraZeneca, Acad House,136 Hills Rd, Cambridge CB2 8PA, Cambs, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 05期
关键词：
D O I：
10.1016/j.jtho.2018.02.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 6 条
[1]  
[Anonymous], ANN ONCOL S5
[2]   A REVIEW OF HEALTH STATE UTILITY VALUES USED IN UK NICE APPRAISALS IN ADVANCED NSCLC [J].
Dansk, V ;
Large, S. ;
Bertranou, E. ;
Bodnar, C. ;
Dyer, M. T. ;
Ryan, J. .
VALUE IN HEALTH, 2016, 19 (07) :A745-A745
[3]   Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI [J].
Mann, Helen ;
Andersohn, Frank ;
Bodnar, Carolyn ;
Mitsudomi, Tetsuya ;
Mok, Tony S. K. ;
Yang, James Chih-Hsin ;
Hoyle, Christopher .
CLINICAL DRUG INVESTIGATION, 2018, 38 (04) :319-331
[4]   Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].
Mok, T. S. ;
Wu, Y. -L. ;
Ahn, M. -J. ;
Garassino, M. C. ;
Kim, H. R. ;
Ramalingam, S. S. ;
Shepherd, F. A. ;
He, Y. ;
Akamatsu, H. ;
Theelen, W. S. M. E. ;
Lee, C. K. ;
Sebastian, M. ;
Templeton, A. ;
Mann, H. ;
Marotti, M. ;
Ghiorghiu, S. ;
Papadimitrakopoulou, V. A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640
[5]   Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses [J].
Mok, Tony S. K. ;
Kim, Sang-We ;
Wu, Yi-Long ;
Nakagawa, Kazuhiko ;
Yang, Jin-Ji ;
Ahn, Myung-Ju ;
Wang, Jie ;
Yang, James Chih-Hsin ;
Lu, You ;
Atagi, Shinji ;
Ponce, Santiago ;
Shi, Xiaojin ;
Rukazenkov, Yuri ;
Haddad, Vincent ;
Thress, Kenneth S. ;
Soria, Jean-Charles .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) :4027-+
[6]   Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy [J].
Wu, Bin ;
Gu, Xiaohua ;
Zhang, Qiang .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) :184-193
1